Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiovascular Divisions Boost Medtronic's FYQ2 Top-Line As Hurricane Recovery Continues

Executive Summary

Medtronic's revenue of $7.1bn for the second fiscal quarter of 2018 was down 4% year-over-year on an as-reported basis, but up 4% on a comparable constant-currency basis. –It would have been even greater if not for the hurricane that hindered manufacturing operations in Puerto Rico, the company reported Nov 21.


Related Content

Medtronic Lowers Hurricane Maria Cost Estimates
US FDA Approves Medtronic's HVAD For Destination Therapy
Market Advantage Of 'MR-Conditional' Device Labeling Fades
Medtronic Launches Advanced Chronic Pain Management System
OUS Approvals: Cardiovascular Devices Lead Modest List In July
US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk
Medtronic Hits Targets In 'Solid' Fiscal 2017
Cardinal Health, Medtronic Tie Up $6.1bn Lower-Margin Assets Deal
Device Debuts: Medtronic, Boston Scientific, Philips, Seventh Sense, Vortex, 410 Medical
FDA To Meet With Medtronic On Drug Pump Risks; Warning Letter Sent


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts